BioSpace News Archive

Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today reported financial results for the third quarter of 2021.

Vaxxinity, Inc. announced the closing of its IPO of 6,000,000 shares of class A common stock at a public offering price of $13 per share on Nov 15, 2021 as well as the subsequent closing on Nov 18, 2021 of the issuance of an additional 537,711 shares of class A common stock, pursuant to a 30-day option granted to the underwriters to purchase up to an additional 900,000 shares of class A common stock at the initial public offering price, less underwriting discounts and commissions.

RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, announced plans to participate in the upcoming virtual Ophthalmology Day at BTIG.

Marker Therapeutics, Inc. (NASDAQ: MRKR), today announced that data from a Phase 1 study investigating its MultiTAA-specific T cells were selected for oral presentation at the 2021 American Society of Hematology (ASH) Annual Meeting.

Gilead Sciences, Inc. announced that its executives will be speaking at the following investor conference.

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), today announced it is discontinuing development of EDP-721, an oral HBV RNA destabilizer, based on emerging safety observations in the single ascending dose part of a Phase 1 study in healthy volunteers.

GENFIT is proud to announce that NIS4® technology’s utility has been recognized in a Stage 1 study1 undertaken by the Non-Invasive Biomarkers of Metabolic Liver Disease initiative of the Foundation for the National Institutes of Health’s Biomarkers Consortium as demonstrating a unique performance in identifying patients with “at-risk” Non-Alcoholic Steatohepatitis.

QurAlis Corporation, a biotech company developing breakthrough precision medicines for amyotrophic lateral sclerosis and other neurodegenerative diseases with genetically validated targets, announced that its CEO and co-founder, Kasper Roet, PhD, will present an update about the company at the 33rd Annual Piper Sandler Virtual Healthcare Conference.

Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that Ryan Spencer, Chief Executive Officer, will participate in a virtual fireside chat at the 4th Annual Evercore virtual ISI HealthCONx Conference.

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Samir Gharib, Chief Financial Officer, will present at the Piper Sandler 33rd Annual Virtual Healthcare Conference.